Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). However, many patients have disease that does not respond to bortezomib, whereas others develop resi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fijs W. B., Chanan-Khan, Asher A., Orlowski, Robert Z.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2200918/
https://ncbi.nlm.nih.gov/pubmed/17591945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-01-065888
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados